摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Tert-butyl-[3-(5-fluoro-4-oxo-3-phenylquinazolin-2-yl)propyl]carbamic acid

中文名称
——
中文别名
——
英文名称
Tert-butyl-[3-(5-fluoro-4-oxo-3-phenylquinazolin-2-yl)propyl]carbamic acid
英文别名
tert-butyl-[3-(5-fluoro-4-oxo-3-phenylquinazolin-2-yl)propyl]carbamic acid
Tert-butyl-[3-(5-fluoro-4-oxo-3-phenylquinazolin-2-yl)propyl]carbamic acid化学式
CAS
——
化学式
C22H24FN3O3
mdl
——
分子量
397.4
InChiKey
SZMYMEFTKUSDKR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    29
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.32
  • 拓扑面积:
    73.2
  • 氢给体数:
    1
  • 氢受体数:
    5

文献信息

  • [EN] PROCESS FOR THE PREPARATION OF AMORPHOUS IDELALISIB AND ITS PREMIX<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION D'IDÉLALISIB AMORPHE ET SON MÉLANGE PRÉLIMINAIRE
    申请人:MYLAN LABORATORIES LTD
    公开号:WO2016147206A1
    公开(公告)日:2016-09-22
    Processes for the preparation of amorphous idelalisib are provided. Processes for the preparation of a premix of amorphous idelalisib are also provided.
    提供了制备非晶态idelalisib的过程。还提供了制备非晶态idelalisib预混物的过程。
  • [EN] SUBSTITUTED 2-AMINO PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE À SUBSTITUTION 2-AMINO SERVANT DE COMPOSÉS INHIBITEURS DE KINASE
    申请人:AURIGENE DISCOVERY TECH LTD
    公开号:WO2014106800A2
    公开(公告)日:2014-07-10
    The present invention provides novel substituted 2-amino pyrimidine derivatives kinase enzyme inhibitor compounds of formula (1), which may be therapeutically useful kinase inhibitor, more particularly PI3K inhibitors. Formula (1) in which A, R1, R2 R3. R4, Q and 'n' have the same meanings given in the specification, and pharmaceutically acceptable salts and stereoisomers thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly PI3K enzyme. The present invention also provides methods for synthesizing and administering the kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
查看更多